What is Angiodynamic Inc Annual Revenue?

Angiodynamic Inc Annual Revenue fell 10.28%, in the last year to $303.91 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

What is Angiodynamic Inc Annual Net Profit?

Angiodynamic Inc Annual Net Profit fell 251.53% in the last year to $184.35 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

What is Angiodynamic Inc Price to Earning Ratio?

Angiodynamic Inc Price to Earning Ratio is -8.98, which is negative.

What is Angiodynamic Inc Stock Price?

Angiodynamic Inc Stock Price rose 46.17% and outperformed its sector by 41.28% in the past year.

What is Angiodynamic Inc Quarterly Revenue?

Angiodynamic Inc Quarterly Revenue fell 4.23% YoY to $72 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

What is Angiodynamic Inc Quarterly Net profit?

Angiodynamic Inc Quarterly Net profit rose 97.65% YoY to $4.41 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

What is Angiodynamic Inc Debt to Equity Ratio?

Angiodynamic Inc Debt to Equity Ratio of 0.02 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Angiodynamic Inc Return on Equity(ROE)?

Angiodynamic Inc Return on Equity(ROE) for the last financial year was -63.15%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Angiodynamic Inc Mutual Fund Holding?

Angiodynamic Inc Mutual Fund Holding decreased by 0.72% in the last quarter to 43.37.

What is Angiodynamic Inc Promoter Share Holding?

Angiodynamic Inc Promoter Share Holding decreased by 0.01% in the most recent quarter to 4.32%.

What is Angiodynamic Inc Institutional Holding?

Angiodynamic Inc Institutional Holding decreased by 0.05% in the last quarter to 84.02.

How is the Angiodynamic Inc today?

The Angiodynamic Inc today is trading in the down by -3.89% at 9.15.

How has Angiodynamic Inc performed historically?

The Angiodynamic Inc is currently trading down -3.89% on an intraday basis in the past week the index fell -1.51%. The index has been down -26.39% in the past quarter and rose 46.17% in the past year. You can view this in the overview section.

Angiodynamic Inc XNAS: ANGO

Angiodynamic Inc Live Share Price Today, Share Analysis and Chart

Name: Angiodynamic Inc: Is Infosys Ltd. worth buying?
Item: Angiodynamic Inc
Rating: 1.133472375
Author: Trendlyne DVM scores

Momentum Trap

Download real time

9.15 -0.37 (-3.89%)

32.22% Fall from 52W High

93,193 XNAS Volume

XNAS 21 Apr, 2025 1:44 PM (EDT)

Angiodynamic Inc Key Metrics

My Metrics

Select

Market Capitalization Below industry Median Unavailable in chosen country	371.6
PE TTM Negative PE TTM Unavailable in chosen country	-9
PEG TTM Negative PEG TTM Unavailable in chosen country	-0.1
Price to Book Below industry Median Unavailable in chosen country	2
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	84
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-4.2
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-12.6
Net Profit Qtr Growth YoY % High in industry Unavailable in chosen country	97.7
Net Profit TTM Growth % High in industry Unavailable in chosen country	78.5
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-9.3
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-17.1
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-63.1
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-43.4

All financials are in USD Million and price data in USD

Low Financial Strength

5.6 / 100

Expensive Valuation

20.2 / 100

Technically Neutral

59.4 / 100

Momentum Trap These stocks are the ones with poor quality and also financials and technical ranging from bad to medium score. This indicates that investors should be highly watchful with these stocks. View Similar Embed DVM

1Yr Price target upside is 71%

3 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Angiodynamic Inc Stock Price Analysis

Day Price Range -3.9% 1 Day return Unavailable in chosen country	9.2 (LTP) 9.19.4 LowHigh
Week Price Range -1.5% 1 Week return Unavailable in chosen country	9.2 (LTP) 9.19.9 LowHigh
Month Price Range -7.3% 1 Month return Unavailable in chosen country	9.2 (LTP) 8.711.7 LowHigh
52 Week Price Range 46.2% 1 Year return Unavailable in chosen country	9.2 (LTP) 5.513.5 LowHigh

View full Share Price History

Angiodynamic Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Angiodynamic Inc's Revenue was higher than average estimate 2 times in past 2 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-4.6

Avg. Estimate

-0.9

Low Estimate

-0.9

High Estimate

-0.9

Current EPS

Avg. Estimate

Hit

EPS is expected to grow by 79.7% in FY25

Consensus Recommendation

3 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 3 analysts for Angiodynamic Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Angiodynamic Inc Stock Analysis

Angiodynamic Inc stock analysis with key metrics, changes, and trends.

Angiodynamic Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Revenue	$303.91 M	10.28%	negative	Annual Revenue fell 10.28%, in the last year to $303.91 M. Its sector's average revenue growth for the last fiscal year was 8.57%.
Annual Net Profit	$184.35 M	251.53%	negative	Annual Net Profit fell 251.53% in the last year to $184.35 M. Its sector's average net profit growth for the last fiscal year was 4.36%.
Price to Earning Ratio	-8.98	-	negative	Price to Earning Ratio is -8.98, which is negative.
Stock Price	$9.15	46.17%	positive	Stock Price rose 46.17% and outperformed its sector by 41.28% in the past year.
Quarterly Revenue	$72 M	4.23%	negative	Quarterly Revenue fell 4.23% YoY to $72 M. Its sector's average revenue growth YoY for the quarter was 8.5%.
Quarterly Net profit	$4.41 M	97.65%	positive	Quarterly Net profit rose 97.65% YoY to $4.41 M. Its sector's average net profit growth YoY for the quarter was 32.89%.
Debt to Equity Ratio	0.02	-	positive	Debt to Equity Ratio of 0.02 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-63.15 %	-63.15%	negative	Return on Equity(ROE) for the last financial year was -63.15%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	43.37 %	-0.72%	negative	Mutual Fund Holding decreased by 0.72% in the last quarter to 43.37.
Promoter Share Holding	4.32 %	-0.01%	negative	Promoter Share Holding decreased by 0.01% in the most recent quarter to 4.32%.
Institutional Holding	84.02 %	-0.05%	negative	Institutional Holding decreased by 0.05% in the last quarter to 84.02.

VIEW LESS

Loading data..

Angiodynamic Inc - Company Profile

What does Angiodynamic Inc do?

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

2024

Gross Remuneration

Year

Angiodynamic Inc Live Share Price Today, Share Analysis and Chart

32.22% Fall from 52W High

Angiodynamic Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

ROE Annual %

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

RoA Annual %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Angiodynamic Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Angiodynamic Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Angiodynamic Inc's Revenue was higher than average estimate 2 times in past 2 years

EPS forecast

EPS is expected to grow by 79.7% in FY25

Consensus Recommendation

The consensus recommendation from 3 analysts for Angiodynamic Inc is STRONG BUY

Angiodynamic Inc Stock Analysis

Angiodynamic Inc stock analysis with key metrics, changes, and trends.

Annual Revenue fell 10.28%, in the last year to $303.91 M. Its sector's average revenue growth for the last fiscal year was 8.57%.

Annual Net Profit fell 251.53% in the last year to $184.35 M. Its sector's average net profit growth for the last fiscal year was 4.36%.

Price to Earning Ratio is -8.98, which is negative.

Stock Price rose 46.17% and outperformed its sector by 41.28% in the past year.

Quarterly Revenue fell 4.23% YoY to $72 M. Its sector's average revenue growth YoY for the quarter was 8.5%.

Quarterly Net profit rose 97.65% YoY to $4.41 M. Its sector's average net profit growth YoY for the quarter was 32.89%.

Debt to Equity Ratio of 0.02 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -63.15%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.72% in the last quarter to 43.37.

Promoter Share Holding decreased by 0.01% in the most recent quarter to 4.32%.

Institutional Holding decreased by 0.05% in the last quarter to 84.02.

Angiodynamic Inc - Company Profile

What does Angiodynamic Inc do?

Angiodynamic Inc Management structure

Mr. James C. Clemmer

Director, President and Chief Executive Officer

Mr. Stephen A. Trowbridge

Principal Accounting Officer, Executive Vice President and Chief Financial Officer

Ms. Laura Piccinini

Senior Vice President and General Manager, Endovascular Therapies and International

Mr. Chad Thomas Campbell

Senior Vice President and General Manager, Global Oncology and Vascular Access

Mr. Warren G. Nighan, Jr

Senior Vice President, Global Supply Chain, Quality and Regulatory Affairs

Mr. David D. Helsel

Senior Vice President, Global Operations and Research and Development

Angiodynamic Inc Board of directors

Mr. Howard W. Donnelly

Chairman of the Board

Mr. Wesley E. Johnson, Jr

Independent Director